What Is The Long-term Outlook for AMC Stock?
Meme stock extraordinaire AMC Entertainment Holdings, Inc. (NYSE:AMC) has long…
Sell
15
IFRX Quote, Financials, Valuation and Earnings
Last price:
$0.84
Seasonality move
:
8.64%
Day range:
$0.77 - $0.85
52-week range:
$0.71 - $2.82
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
277.49x
P/B ratio:
0.75x
Volume:
329.2K
Avg. volume:
663.9K
1-year change:
-48.15%
Market cap:
$56.9M
Revenue:
$179.4K
EPS (TTM):
-$0.81
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IFRX
InflaRx NV
|
$36.3K | -$0.20 | 256.48% | -10.49% | $3.62 |
|
CDT
Conduit Pharmaceuticals
|
-- | -- | -- | -- | -- |
|
LENZ
LENZ Therapeutics
|
-- | -$0.32 | -- | -26.67% | $44.50 |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | -- |
|
MAZE
Maze Therapeutics
|
-- | -$0.63 | 25% | -1571.33% | $25.00 |
|
ORKA
Oruka Therapeutics
|
-- | -$0.48 | -- | -42.18% | $39.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IFRX
InflaRx NV
|
$0.84 | $3.62 | $56.9M | -- | $0.00 | 0% | 277.49x |
|
CDT
Conduit Pharmaceuticals
|
$2.45 | -- | $2M | -- | $0.00 | 0% | -- |
|
LENZ
LENZ Therapeutics
|
$29.52 | $44.50 | $830.9M | -- | $1.03 | 0% | -- |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
MAZE
Maze Therapeutics
|
$11.41 | $25.00 | $488.7M | -- | $0.00 | 0% | -- |
|
ORKA
Oruka Therapeutics
|
$11.63 | $39.50 | $435.4M | -- | $19.36 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IFRX
InflaRx NV
|
-- | 1.638 | -- | 3.85x |
|
CDT
Conduit Pharmaceuticals
|
-- | 0.069 | -- | -- |
|
LENZ
LENZ Therapeutics
|
-- | 0.835 | -- | -- |
|
LIMN
Liminatus Pharma
|
-- | 0.000 | -- | -- |
|
MAZE
Maze Therapeutics
|
-- | 0.000 | -- | -- |
|
ORKA
Oruka Therapeutics
|
-- | -0.312 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IFRX
InflaRx NV
|
-$9.8K | -$13.7M | -56.78% | -56.78% | 1207051.66% | -$14.8M |
|
CDT
Conduit Pharmaceuticals
|
-- | -$4M | -- | -- | -- | -$4.3M |
|
LENZ
LENZ Therapeutics
|
-- | -$16.9M | -- | -- | -- | -$16.2M |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | -- | -- |
|
MAZE
Maze Therapeutics
|
-- | -- | -- | -- | -- | -- |
|
ORKA
Oruka Therapeutics
|
-- | -$25.1M | -- | -- | -- | -$20.9M |
InflaRx NV vs. Competitors
-
Which has Higher Returns IFRX or CDT?
Conduit Pharmaceuticals has a net margin of -14092.9% compared to InflaRx NV's net margin of --. InflaRx NV's return on equity of -56.78% beat Conduit Pharmaceuticals's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IFRXInflaRx NV-5376.61% -$0.14 $63.9M CDTConduit Pharmaceuticals-- -$19.80 -- -
What do Analysts Say About IFRX or CDT?
InflaRx NV has a consensus price target of $3.62, signalling upside risk potential of 330.72%. On the other hand Conduit Pharmaceuticals has an analysts' consensus of -- which suggests that it could fall by --. Given that InflaRx NV has higher upside potential than Conduit Pharmaceuticals, analysts believe InflaRx NV is more attractive than Conduit Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings IFRXInflaRx NV5 1 0 CDTConduit Pharmaceuticals0 0 0 -
Is IFRX or CDT More Risky?
InflaRx NV has a beta of 1.287, which suggesting that the stock is 28.694% more volatile than S&P 500. In comparison Conduit Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IFRX or CDT?
InflaRx NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Conduit Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InflaRx NV pays -- of its earnings as a dividend. Conduit Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IFRX or CDT?
InflaRx NV quarterly revenues are -$450, which are larger than Conduit Pharmaceuticals quarterly revenues of --. InflaRx NV's net income of -$8.7M is lower than Conduit Pharmaceuticals's net income of -$5.1M. Notably, InflaRx NV's price-to-earnings ratio is -- while Conduit Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InflaRx NV is 277.49x versus -- for Conduit Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IFRXInflaRx NV277.49x -- -$450 -$8.7M CDTConduit Pharmaceuticals-- -- -- -$5.1M
-
Which has Higher Returns IFRX or LENZ?
LENZ Therapeutics has a net margin of -14092.9% compared to InflaRx NV's net margin of --. InflaRx NV's return on equity of -56.78% beat LENZ Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IFRXInflaRx NV-5376.61% -$0.14 $63.9M LENZLENZ Therapeutics-- -$0.53 -- -
What do Analysts Say About IFRX or LENZ?
InflaRx NV has a consensus price target of $3.62, signalling upside risk potential of 330.72%. On the other hand LENZ Therapeutics has an analysts' consensus of $44.50 which suggests that it could grow by 50.75%. Given that InflaRx NV has higher upside potential than LENZ Therapeutics, analysts believe InflaRx NV is more attractive than LENZ Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings IFRXInflaRx NV5 1 0 LENZLENZ Therapeutics5 0 0 -
Is IFRX or LENZ More Risky?
InflaRx NV has a beta of 1.287, which suggesting that the stock is 28.694% more volatile than S&P 500. In comparison LENZ Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IFRX or LENZ?
InflaRx NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENZ Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $1.03 per share. InflaRx NV pays -- of its earnings as a dividend. LENZ Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IFRX or LENZ?
InflaRx NV quarterly revenues are -$450, which are larger than LENZ Therapeutics quarterly revenues of --. InflaRx NV's net income of -$8.7M is higher than LENZ Therapeutics's net income of -$14.6M. Notably, InflaRx NV's price-to-earnings ratio is -- while LENZ Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InflaRx NV is 277.49x versus -- for LENZ Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IFRXInflaRx NV277.49x -- -$450 -$8.7M LENZLENZ Therapeutics-- -- -- -$14.6M
-
Which has Higher Returns IFRX or LIMN?
Liminatus Pharma has a net margin of -14092.9% compared to InflaRx NV's net margin of --. InflaRx NV's return on equity of -56.78% beat Liminatus Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IFRXInflaRx NV-5376.61% -$0.14 $63.9M LIMNLiminatus Pharma-- -- -- -
What do Analysts Say About IFRX or LIMN?
InflaRx NV has a consensus price target of $3.62, signalling upside risk potential of 330.72%. On the other hand Liminatus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that InflaRx NV has higher upside potential than Liminatus Pharma, analysts believe InflaRx NV is more attractive than Liminatus Pharma.
Company Buy Ratings Hold Ratings Sell Ratings IFRXInflaRx NV5 1 0 LIMNLiminatus Pharma0 0 0 -
Is IFRX or LIMN More Risky?
InflaRx NV has a beta of 1.287, which suggesting that the stock is 28.694% more volatile than S&P 500. In comparison Liminatus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IFRX or LIMN?
InflaRx NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Liminatus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InflaRx NV pays -- of its earnings as a dividend. Liminatus Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IFRX or LIMN?
InflaRx NV quarterly revenues are -$450, which are larger than Liminatus Pharma quarterly revenues of --. InflaRx NV's net income of -$8.7M is higher than Liminatus Pharma's net income of --. Notably, InflaRx NV's price-to-earnings ratio is -- while Liminatus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InflaRx NV is 277.49x versus -- for Liminatus Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IFRXInflaRx NV277.49x -- -$450 -$8.7M LIMNLiminatus Pharma-- -- -- --
-
Which has Higher Returns IFRX or MAZE?
Maze Therapeutics has a net margin of -14092.9% compared to InflaRx NV's net margin of --. InflaRx NV's return on equity of -56.78% beat Maze Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IFRXInflaRx NV-5376.61% -$0.14 $63.9M MAZEMaze Therapeutics-- -- -- -
What do Analysts Say About IFRX or MAZE?
InflaRx NV has a consensus price target of $3.62, signalling upside risk potential of 330.72%. On the other hand Maze Therapeutics has an analysts' consensus of $25.00 which suggests that it could grow by 119.11%. Given that InflaRx NV has higher upside potential than Maze Therapeutics, analysts believe InflaRx NV is more attractive than Maze Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings IFRXInflaRx NV5 1 0 MAZEMaze Therapeutics3 0 0 -
Is IFRX or MAZE More Risky?
InflaRx NV has a beta of 1.287, which suggesting that the stock is 28.694% more volatile than S&P 500. In comparison Maze Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IFRX or MAZE?
InflaRx NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Maze Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InflaRx NV pays -- of its earnings as a dividend. Maze Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IFRX or MAZE?
InflaRx NV quarterly revenues are -$450, which are larger than Maze Therapeutics quarterly revenues of --. InflaRx NV's net income of -$8.7M is higher than Maze Therapeutics's net income of --. Notably, InflaRx NV's price-to-earnings ratio is -- while Maze Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InflaRx NV is 277.49x versus -- for Maze Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IFRXInflaRx NV277.49x -- -$450 -$8.7M MAZEMaze Therapeutics-- -- -- --
-
Which has Higher Returns IFRX or ORKA?
Oruka Therapeutics has a net margin of -14092.9% compared to InflaRx NV's net margin of --. InflaRx NV's return on equity of -56.78% beat Oruka Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IFRXInflaRx NV-5376.61% -$0.14 $63.9M ORKAOruka Therapeutics-- -$0.40 -- -
What do Analysts Say About IFRX or ORKA?
InflaRx NV has a consensus price target of $3.62, signalling upside risk potential of 330.72%. On the other hand Oruka Therapeutics has an analysts' consensus of $39.50 which suggests that it could grow by 239.64%. Given that InflaRx NV has higher upside potential than Oruka Therapeutics, analysts believe InflaRx NV is more attractive than Oruka Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings IFRXInflaRx NV5 1 0 ORKAOruka Therapeutics7 0 0 -
Is IFRX or ORKA More Risky?
InflaRx NV has a beta of 1.287, which suggesting that the stock is 28.694% more volatile than S&P 500. In comparison Oruka Therapeutics has a beta of -0.380, suggesting its less volatile than the S&P 500 by 137.95%.
-
Which is a Better Dividend Stock IFRX or ORKA?
InflaRx NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oruka Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $19.36 per share. InflaRx NV pays -- of its earnings as a dividend. Oruka Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IFRX or ORKA?
InflaRx NV quarterly revenues are -$450, which are larger than Oruka Therapeutics quarterly revenues of --. InflaRx NV's net income of -$8.7M is higher than Oruka Therapeutics's net income of -$21M. Notably, InflaRx NV's price-to-earnings ratio is -- while Oruka Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InflaRx NV is 277.49x versus -- for Oruka Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IFRXInflaRx NV277.49x -- -$450 -$8.7M ORKAOruka Therapeutics-- -- -- -$21M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is NuScale the Best Nuclear Stock to Buy?
NuScale Power (NYSE:SMR) is a nuclear power startup that has…
Where Will Kestra Medical Stock Be in 1 Year?
Kestra Medical Technologies (NASDAQ:KMTS) is a medical device startup that…
Stock Ideas
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 52x
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 42x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
76
AVAV alert for Jun 26
AeroVironment [AVAV] is up 13.82% over the past day.
Buy
51
SITM alert for Jun 26
SiTime [SITM] is up 2.17% over the past day.
Buy
54
NGVC alert for Jun 26
Natural Grocers by Vitamin Cottage [NGVC] is down 3.21% over the past day.
